Wikipedia -WSS

Wikipedia

author：fashion 2025-10-02 23:30:09 - browse：6

An ALS patient receives support. -- health coverage from STAT — Adobe

Years of polarizing scientific discourse and bruising online debate will come to a head next week when advisers to the Food and Drug Administration weigh in on NurOwn, a potential treatment to slow the progression of ALS that has bitterly divided physicians and patient advocates.

On Sept. 27, a panel of experts will consider the convoluted data supporting the potential approval of NurOwn, a stem-cell therapy the FDA previously refused to even consider. To some physicians, the drug’s failure to show significant benefits in clinical studies leaves approval out of the question. Others, including the influential ALS Association, say NurOwn’s manufacturer, a small biotech firm called BrainStorm Cell Therapeutics, hasn’t disclosed enough information to properly determine the medicine’s value.

Another group of patients and doctors argue that NurOwn’s supporting evidence, while problematic, justifies making it available to the roughly 30,000 ALS patients in the U.S., people for whom there is currently no hope of arresting an incurable disease that gradually erodes motor function and leads to death within about five years of diagnosis.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medical records are filled with copy
Next article： FDA clears AI tool for detecting skin cancer

knowledge

WSS

Titanic submersible: What a 'catastrophic implosion' means and what officials found

My yearlong odyssey to get my son’s ADHD medication covered

Eli Lilly, Pfizer, and others want in on the online prescription market

Florida group launches initiative to get abortion constitutional amendment on 2024 ballot

Another man arrested in connection with shooting at Kansas nightclub

North Korean leader's powerful sister says warplanes repelled US spy plane

focus

Wikipedia

hotspot

How to save PrEP access — and even expand it

Titanic submersible: What a 'catastrophic implosion' means and what officials found

DIEP, the 'gold standard' of breast reconstruction, is under threat

Florida group launches initiative to get abortion constitutional amendment on 2024 ballot

As demand for Covid shots wanes, Moderna seeks its next success

House panel to mark up pandemic

Bright Health sells Medicare Advantage business to Molina

Rare Northern Lights show in US this week: Where and how to see it

23andMe had bad news about my health. I wish a person had delivered it

Gilead’s Trodelvy fails in lung cancer, raises questions on ADCs

hotspot

Francis Collins on trust in science and how Covid communications failed

Kansas must stop changing trans people's sex listing on driver's licenses, judge says

Test for long Covid? Researchers find new clue in blood samples

Readout Newsletter: BridgeBio, Madrigal, and Silicon Valley Bank

Parkinson’s finding may lead to tests and, someday, treatments

NIH director takes cautious approach to Biden drug pricing priority

explore

knowledge

explore

leisure time